Antiretrovirals Linked to Cumulative Kidney RiskAntiretrovirals Linked to Cumulative Kidney Risk
The chance of developing chronic kidney disease increases steadily in patients taking tenofovir, ritonavir-boosted atazanavir, or ritonavir-enhanced lopinavir, researchers warn. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 27, 2015 Category: Consumer Health News Tags: HIV/AIDS News Source Type: news
FDA Approves Changes to Kaletra Label
"On January 28, [2015] FDA approved changes to the Kaletra (lopinavir/ritonavir) label to include dosing recommendations in pregnant women."
More information is available:
FDA: Press release
AIDSinfo: Patient fact sheet on Kaletra (Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS))
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - January 30, 2015 Category: Infectious Diseases Source Type: news
Triple Antiviral Therapy Promising for Mild - to - Moderate COVID - 19
Duration of viral shedding shorter with combination of lopinavir - ritonavir, ribavarin, interferon beta - 1b (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - November 11, 2014 Category: Respiratory Medicine Tags: Infections, Nursing, Pharmacy, Pulmonology, Critical Care, Emergency Medicine, Journal, Source Type: news
FDA Updates Etravirine Labeling
"On August 20, 2014, the Intelence (etravirine) label was updated to include information regarding coadministration of etravirine with the following drugs:
"dolutegravir, dolutegravir/darunavir/ritonavir, dolutegravir/lopinavir/ritonavir
"atazanavir/ritonavir
"boceprevir"
The updated labeling for etravirine is available at the FDA website.
More information is available:
FDA: Press release
AIDSinfo: Patient fact sheet on etravirine (Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health an...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - August 29, 2014 Category: Infectious Diseases Source Type: news
Dual Therapy Effective in Newly Diagnosed HIV-1 InfectionDual Therapy Effective in Newly Diagnosed HIV-1 Infection
In previously untreated adults with HIV-1 infection, dual therapy with lopinavir and ritonavir plus lamivudine is as effective as triple therapy with lopinavir and ritonavir plus two NRTIs. Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - May 12, 2014 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news
Uganda: HIV Drugs Could Treat Cervical Cancer - Study
[Observer]A commonly used oral combination HIV drug of lopinavir and ritonavir could be taken as a vaginal capsule to kill the virus that leads to cervical cancer in women, a phase I clinical trial in Kenya reveals. Cervical cancer is caused by the uncontrolled growth of some cells on the cervix (the organ connecting the uterus to the vagina). Cells on the cervix begin to grow slowly and abnormally over several years. (Source: AllAfrica News: HIV-Aids and STDs)
Source: AllAfrica News: HIV-Aids and STDs - April 30, 2014 Category: Infectious Diseases Source Type: news
Could a Commonly Prescribed HIV Drug Prevent Cervical Cancer?
We have to admit we were somewhat startled last week by news that lopinavir, the key agent in the HIV protease inhibitor-class drug Kaletra, is apparently able to wipe out pre-cancerous cells associated with the development of cervical cancer....Read Full Post (Source: About AIDS / HIV)
Source: About AIDS / HIV - February 24, 2014 Category: Consumer Health News Source Type: news
[Press Release] Proposed Shake-up on Drug-Pricing at Global Fund Risks Higher Costs for Middle Income Countries and Donors
Myanmar 2012 © Sami Siva
A patient shows a daily dose of his medication for extensively drug-resistant tuberculosis
GENEVA/NEW YORK, DECEMBER 2, 2013—Ahead of the Global Fund replenishment conference in Washington, DC, this week, the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) has warned the Global Fund to Fight AIDS, Tuberculosis, and Malaria of the consequences of spearheading a new pricing initiative that could result in middle-income countries paying significantly higher prices for medicines to combat diseases including HIV and t...
Source: MSF News - December 3, 2013 Category: Global & Universal Source Type: news
Proposed shake-up to drug pricing framework risks middle-income countries paying more
International medical humanitarian organization Médecins Sans Frontières (MSF) has warned the Global Fund to Fight AIDS, Tuberculosis and Malaria of the consequences of a new pricing initiative that could result in middle-income countries paying significantly higher prices for medicines to combat diseases including HIV and tuberculosis. The warning comes ahead of the Global Fund replenishment conference in Washington, DC, this week.
“MSF programs are already seeing how middle-income countries like Ukraine, Honduras, or Thailand pay exorbitant prices for drugs and vaccines because of the tiered pricing policies pursued...
Source: MSF News - December 2, 2013 Category: Global & Universal Tags: Access Campaign NEWS Frontpage Generic Drugs HIV / AIDS Source Type: news
Proposed Shake-up on Drug-Pricing at Global Fund Risks Higher Costs for Middle Income Countries and Donors
Myanmar 2012 © Sami Siva
A patient shows a daily dose of his medication for extensively drug-resistant tuberculosis
GENEVA/NEW YORK, DECEMBER 2, 2013—Ahead of the Global Fund replenishment conference in Washington, DC, this week, the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) has warned the Global Fund to Fight AIDS, Tuberculosis, and Malaria of the consequences of spearheading a new pricing initiative that could result in middle-income countries paying significantly higher prices for medicines to combat diseases including HIV and t...
Source: MSF News - December 2, 2013 Category: Global & Universal Source Type: news
Low-Dose Drug Combo Safe in Kids with HIV (CME/CE)
KUALA LUMPUR (MedPage Today) -- A low-dose treatment regimen with lopinavir/ritonavir antiretroviral therapy appears to have similar efficacy with fewer adverse events than standard dosing in HIV-infected children, researchers said here. (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - July 5, 2013 Category: Consumer Health News Source Type: news
HIV Drug Not Tied to Premature Births (CME/CE)
ATLANTA (MedPage Today) -- Pregnant HIV-infected women treated with a lopinavir/ritonavir (Kaletra)-based antiretroviral regimen are at no greater risk of delivering a preterm baby than those given an efavirenz (Sustiva)-based treatment, researchers said. (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - March 8, 2013 Category: Consumer Health News Source Type: news
Generics in Global Antivirals Market Forecast to Reach $9.2 Billion by...
Research and Markets Announces the Addition of GBI's Research "Generics in the Antivirals Market to 2018 - Launch of Generic Combivir and Patent Expiry of Sustiva, Kaletra and Epivir-HBV will...(PRWeb February 14, 2013)Read the full story at http://www.prweb.com/releases/2013/2/prweb10433563.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 15, 2013 Category: Pharmaceuticals Source Type: news
HIV/AIDS Update - Kaletra (lopinavir/ritonavir) label update: drug interaction information
On January 17, 2013, FDA approved revisions to the Kaletra
(lopinavir/ritonavir) labels to include new drug interaction
information. The following updates were included.
Anticoagulants: Rivaroxaban. Avoid concomitant use of rivaroxaban
and Kaletra.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 23, 2013 Category: Pharmaceuticals Source Type: news
FDA Updates Lopinavir/Ritonavir (Kaletra) Labeling to Include New Drug Interaction Information
"On January 17, 2013, FDA approved revisions to the Kaletra (lopinavir/ritonavir) labels to include new drug interaction information. The following updates were included.
"Anticoagulants: Rivaroxaban. Avoid concomitant use of rivaroxaban and Kaletra. Coadministration of Kaletra and rivaroxaban is expected to result in increased exposure of rivaroxaban which may led to risk of increased bleeding
"Anticonvulsants: Lamotrigine and valproate. Coadministration of Kaletra and lamotrigine or valproate may decrease the exposure of lamotrigine or valproate. A dose increase of the lamotrigine or valproate may be nee...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - January 22, 2013 Category: Infectious Diseases Source Type: news
